Last €0.22 EUR
Change Today -0.005 / -2.24%
Volume 719.5K
As of 5:33 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

natraceutical sa (NTC) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - €0.33
52 Week Low
11/14/14 - €0.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NATRACEUTICAL SA (NTC)

Related News

No related news articles were found.

natraceutical sa (NTC) Related Businessweek News

No Related Businessweek News Found

natraceutical sa (NTC) Details

Natraceutical, S.A. manufactures and sells a range of nutritional products to pharmacies and drugstores in France. The company develops and markets nutritional supplements in the weight control, health, beauty, energy, and OTC segments. It primarily offers weight control products, such as Turbodraine, Calorilight, Minceur 24, and Turboslim; and health products, including Gélée Royale, Chondralgic, Mémorex, and Lixifor in the areas of anti-stress, joint pain, memory and concentration, fatigue or body’s defenses, night’s rest, and intestinal functions, as well as a range of products to alleviate the symptoms of menopause. The company also provides tonics and multivitamins comprising Vitalité 4G and Acerola for the recovery of energy tone and the improvement of male sexuality; and beauty products consisting of Expert Cheveux and Expert Hyaluronic covering skin- and hair-care formulations, antiwrinkles, moisturizers, and hair strengtheners. In addition, it offers five formulations with natural active ingredients extracted from organic farming for use in the circulation, weight control, body detoxification, and vitality; and OTC products, Dormicalm and Venaclar. The company also operates in Spain, Benelux, Austria, Portugal, the United Kingdom, and other countries. Natraceutical, S.A. was incorporated in 1993 and is headquartered in Barcelona, Spain. Natraceutical, S.A. is a subsidiary of Natra, SA.

Founded in 1993

natraceutical sa (NTC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

natraceutical sa (NTC) Key Developments

Natraceutical Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Natraceutical reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the nine months, the company reported revenue of EUR 24.752 million against EUR 25.302 million a year ago, a 2.2% decline mainly due to the decrease of 4.2% occurred in the first half of the year. EBITDA was EUR 2.72 million against EUR 3.36 million a year ago, mainly by the sales decline from the beginning of the year and increased advertising expenditure in the third quarter. Result from operations was EUR 2.368 million against EUR 3.001 million a year ago. Profit before taxes was EUR 2.525 million against EUR 3.108 million a year ago. Net result was EUR 2.525 million against EUR 2.173 million a year ago. For the quarter the company reported turnover of EUR 7.01 million against EUR 6.79 million a year ago. EBITDA was EUR 0.78 million against EUR 0.84 million a year ago.

Natraceutical SA Reports Audited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 2014

Natraceutical SA reported audited consolidated earnings results for the second quarter and six months ended June 2014. In the second quarter, sales of the company stood at €7.64 million, in line with the €7.77 million in the second quarter of 2013. LBITDA was €0.67 million against €0.42 million a year ago. Loss from operations was €0.79 million against €0.53 million a year ago. For the six months, the company reported turnover of €17.74 million compared to €18.51 million a year ago, primarily driven by a 6.0% decline in sales in the first quarter after the change of purchase dynamics in the pharmaceutical channel. EBITDA stood at the end of June at €1.94 million against €2.52 million in the same period last year following the sales variation. At the end of June, bank borrowings amounted to €1.46 million. However, net debt -calculated as bank borrowings less cash and highly liquid financial assets- recorded a cash surplus of €5.16 million. Profit from operations was €1.71 million against €2.3 million a year ago. Profit before taxes was €1.833 million against €2.4 million a year ago. Net result was €1.22 million against €2.4 million a year ago.

Natraceutical SA to Report Q2, 2014 Final Results on Aug 31, 2014

Natraceutical SA announced that they will report Q2, 2014 final results After-Market on Aug 31, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTC:SM €0.22 EUR -0.005

NTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natra SA €1.06 EUR -0.035
View Industry Companies

Industry Analysis


Industry Average

Valuation NTC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 0.8x
Price/Cash Flow 175.5x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATRACEUTICAL SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at